A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control

Archive ouverte

Namineni, Sukumar | O'Connor, Tracy | Faure-Dupuy, Suzanne | Johansen, Pål | Riedl, Tobias | Liu, Kaijing | Xu, Haifeng | Singh, Indrabahadur | Shinde, Prashant | Li, Fanghui | Pandyra, Aleksandra | Sharma, Piyush | Ringelhan, Marc | Muschaweckh, Andreas | Borst, Katharina | Blank, Patrick | Lampl, Sandra | Neuhaus, Katharina | Durantel, David | Farhat, Rayan | Weber, Achim | Lenggenhager, Daniela | Kündig, Thomas | Staeheli, Peter | Protzer, Ulrike | Wohlleber, Dirk | Holzmann, Bernhard | Binder, Marco | Breuhahn, Kai | Assmus, Lisa Mareike | Nattermann, Jacob | Abdullah, Zeinab | Rolland, Maude | Dejardin, Emmanuel | Lang, Philipp | Lang, Karl | Karin, Michael | Lucifora, Julie | Kalinke, Ulrich | Knolle, Percy | Heikenwalder, Mathias

Edité par CCSD ; Elsevier -

International audience. Hepatic innate immune control of viral infections has largely been attributed to Kupffer cells, the liver-resident macrophages. However, hepatocytes, the parenchymal cells of the liver, also possess potent immunological functions in addition to their known metabolic functions. Owing to their abundance in the liver and known immunological functions, we aimed to investigate the direct antiviral mechanisms employed by hepatocytes.

Consulter en ligne

Suggestions

Du même auteur

Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p

Archive ouverte | Faure-Dupuy, Suzanne | CCSD

International audience

HIF1α‐mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence

Archive ouverte | Riedl, Tobias | CCSD

International audience. New therapeutic strategies against Hepatitis B virus (HBV) focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia inducible factor 1...

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Archive ouverte | Pfister, Dominik | CCSD

International audience. Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treati...

Chargement des enrichissements...